Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Bortezomib promotes neutrophil‐mediated bacterial clearance in sepsis by inhibiting plasmablast activation

View through CrossRef
Abstract Background and Purpose Sepsis induces immunosuppression, contributing to high mortality. Plasmablasts, including an IL‐10–producing regulatory subset, expand during sepsis to exert immunosuppressive functions. This study examined how depleting plasmablasts can improve the prognosis of sepsis, and investigated the underlying mechanisms by focusing on neutrophil function. Experimental Approach Plasmablasts were depleted in vivo in CD138‐diphtheria toxin receptor (DTR) transgenic mice subjected to caecal ligation and puncture (CLP)‐induced sepsis. The effects of plasmablast depletion on animal survival, bacterial load, inflammatory mediators, and neutrophil number and function were assessed. The proteasome inhibitor bortezomib (BTZ) was evaluated for its ability to suppress plasmablasts, and its therapeutic efficacy in wild‐type mice with sepsis. Key Results Plasmablast depletion in CD138‐DTR mice was associated with an increase in the number and antibacterial function of neutrophils, including increased production of reactive oxygen species (ROS) and phagocytic capacity. In vitro co‐culture experiments demonstrated that plasmablasts suppressed neutrophil activity, an effect mediated by adenosine and IL‐10 signalling. Treatment of wildtype septic mice with BTZ effectively reduced plasmablast abundance and CD39 expression. BTZ 0.05 mg·kg −1 mirrored the protective effects of genetic ablation, improved survival, reduced bacterial burden and inflammation and improved neutrophil‐mediated bacterial clearance. At high concentrations, BTZ worsened outcomes and is an unlikely magic bullet for sepsis without stringent dosing controls. Conclusion and Implications Plasmablasts contribute to sepsis immunosuppression by affecting neutrophil function. The clinically‐available drug bortezomib can target this population, positioning plasmablast inhibition as a novel and translatable therapeutic strategy to improve bacterial clearance and survival in sepsis.
Title: Bortezomib promotes neutrophil‐mediated bacterial clearance in sepsis by inhibiting plasmablast activation
Description:
Abstract Background and Purpose Sepsis induces immunosuppression, contributing to high mortality.
Plasmablasts, including an IL‐10–producing regulatory subset, expand during sepsis to exert immunosuppressive functions.
This study examined how depleting plasmablasts can improve the prognosis of sepsis, and investigated the underlying mechanisms by focusing on neutrophil function.
Experimental Approach Plasmablasts were depleted in vivo in CD138‐diphtheria toxin receptor (DTR) transgenic mice subjected to caecal ligation and puncture (CLP)‐induced sepsis.
The effects of plasmablast depletion on animal survival, bacterial load, inflammatory mediators, and neutrophil number and function were assessed.
The proteasome inhibitor bortezomib (BTZ) was evaluated for its ability to suppress plasmablasts, and its therapeutic efficacy in wild‐type mice with sepsis.
Key Results Plasmablast depletion in CD138‐DTR mice was associated with an increase in the number and antibacterial function of neutrophils, including increased production of reactive oxygen species (ROS) and phagocytic capacity.
In vitro co‐culture experiments demonstrated that plasmablasts suppressed neutrophil activity, an effect mediated by adenosine and IL‐10 signalling.
Treatment of wildtype septic mice with BTZ effectively reduced plasmablast abundance and CD39 expression.
BTZ 0.
05 mg·kg −1 mirrored the protective effects of genetic ablation, improved survival, reduced bacterial burden and inflammation and improved neutrophil‐mediated bacterial clearance.
At high concentrations, BTZ worsened outcomes and is an unlikely magic bullet for sepsis without stringent dosing controls.
Conclusion and Implications Plasmablasts contribute to sepsis immunosuppression by affecting neutrophil function.
The clinically‐available drug bortezomib can target this population, positioning plasmablast inhibition as a novel and translatable therapeutic strategy to improve bacterial clearance and survival in sepsis.

Related Results

Bortezomib Promotes Neutrophil-Mediated Bacterial Clearance in Sepsis by Inhibiting Plasmablast Activation
Bortezomib Promotes Neutrophil-Mediated Bacterial Clearance in Sepsis by Inhibiting Plasmablast Activation
Background and Purpose: Sepsis induces immunosuppression, contributing to high mortality. Plasmablasts, a regulatory B cell subset that expands during sepsis, are...
Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines
Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines
Abstract Bortezomib is the first proteasome inhibitor in clinical use. It is particularly effective in myeloma compared with other cancers; as a single agent, its re...
First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital
First Year Experience Of Subcutaneous Bortezomib Use In a University Teaching Hospital
Abstract Introduction Subcutaneous (SC) injection of bortezomib was reported to be safe and effective in myeloma patients. In Se...
The Establishment of Bortezomib Resistant Myeloma Cell Line KM3/BTZ and Explore the Resistance Mechanism
The Establishment of Bortezomib Resistant Myeloma Cell Line KM3/BTZ and Explore the Resistance Mechanism
Abstract Background: Multiple myeloma (MM) is an incurable B-cell malignancy resulting in significant morbidity and mortality, the incidence of second place in hemat...
Neurological Complications in Sepsis
Neurological Complications in Sepsis
Background: Sepsis is a medical emergency that requires immediate assessment and management. Sepsis can affect patients at any age group which increases the number of sepsis cases....
Abstract 1269: Molecular changes underlying bortezomib sensitization of cancer cells to TRAIL-mediated apoptosis
Abstract 1269: Molecular changes underlying bortezomib sensitization of cancer cells to TRAIL-mediated apoptosis
Abstract We have previously shown that the proteasome inhibitor bortezomib (Velcade/PS-341) specifically sensitized certain human renal carcinoma (RCC) lines to apop...

Back to Top